SONG-PKD:建立多囊肾病核心结局集的研究方案
常染色体显性多囊肾病(ADPKD)是常见的遗传性肾病,但现有临床试验对患者和临床医生关注的结局报告不一致。SONG-PKD项目计划通过系统评价、焦点小组、定性访谈、国际德尔菲调查和共识研讨会五个阶段,建立基于共识的核心结局集,以改善ADPKD试验结局报告的一致性和完整性。
要点
- ADPKD占终末期肾病(ESKD)病例的5-10%,囊肿可使肾脏增大至正常重量的20倍。
- 现有ADPKD试验中患者相关结局(如症状和生活质量)报告不频繁且不一致。
- SONG-PKD通过五阶段方法建立共识性核心结局集,涵盖患者、照护者、医护人员等多利益相关方。
核心结论
- SONG-PKD核心结局集旨在提高ADPKD试验结局报告的一致性和完整性,从而改善试验证据的可靠性和相关性,最终改善ADPKD患者的照护和结局。
研究设计与样本
- SONG-PKD项目分为五个阶段:系统评价现有PKD试验报告的结局;采用名义组技术的患者和照护者焦点小组;对医护人员进行定性利益相关者访谈;包括所有利益相关群体的国际三轮德尔菲调查;以及共识研讨会。
主要发现
- ADPKD占终末期肾病(ESKD)病例的5-10%。
- 囊肿生长可使肾脏增大至正常肾脏重量的20倍。
- ADPKD患者并发症风险增加,包括肾和肝囊肿、尿路感染、颅内动脉瘤、憩室病和肾疼痛,损害生活质量。
关键数值与推荐
- SONG-PKD的五个阶段:系统评价、焦点小组(名义组技术)、定性利益相关者访谈、国际三轮德尔菲调查、共识研讨会。
- 德尔菲调查包括患者、照护者、医疗提供者、政策制定者、研究人员和行业代表。
临床怎么用
- SONG-PKD核心结局集旨在用于ADPKD试验的结局报告,以提高一致性和完整性,支持治疗决策。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially life threatening inherited kidney disease and is responsible for 5-10% of cases of end-stage kidney disease (ESKD). Cystic kidneys may enlarge up to 20 times the weight of a normal kidney due to the growth of renal cysts, and patients with ADPKD have an increased risk of morbidity, premature mortality, and other life-time complications including renal and hepatic cyst and urinary tract infection, intracranial aneurysm, diverticulosis, and kidney pain which impair quality of life. Despite some therapeutic advances and the growing number of clinical trials in ADPKD, the outcomes that are relevant to patients and clinicians, such as symptoms and quality of life, are infrequently and inconsistently reported. This potentially limits the contribution of trials to inform evidence-based decision-making. The Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) project aims to establish a consensus-based set of core outcomes for trials in PKD (with an initial focus on ADPKD but inclusive of all stages) that patients and health professionals identify as critically important. METHODS: The five phases of SONG-PKD are: a systematic review to identify outcomes that have been reported in existing PKD trials; focus groups with nominal group technique with patients and caregivers to identify, rank, and describe reasons for their choices; qualitative stakeholder interviews with health professionals to elicit individual values and perspectives on outcomes for trials involving patients with PKD; an international three-round Delphi survey with all stakeholder groups (including patients, caregivers, healthcare providers, policy makers, researchers, and industry) to gain consensus on critically important core outcome domains; and a consensus workshop to review and establish a set of core outcome domains and measures for trials in PKD. DISCUSSION: The SONG-PKD core outcome set is aimed at improving the consistency and completeness of outcome reporting across ADPKD trials, leading to improvements in the reliability and relevance of trial-based evidence to inform decisions about treatment and ultimately improve the care and outcomes for people with ADPKD.
引用
- Cho Y, Sautenet B, Rangan G, et al. Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials. 2017. PMID: 29169385. doi:10.1186/s13063-017-2298-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。